Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfenex Pitches Teriparatide Pen Against Lilly's Forteo as Partner Alvogen Files In Europe

Executive Summary

You may also be interested in...



Alvogen And Pfenex Have Teriparatide Filing Accepted By EMA

The EMA has formally accepted for filing Alvogen and Pfenex’ centralized marketing authorization application for a biosimilar rival to Lilly’s Forsteo teriparatide blockbuster.

Rovi Rolls Out Enoxaparin In Portugal As It Prepares For Teriparatide

Rovi has started to market its enoxaparin biosimilar directly in Portugal as the Spanish company prepares to market teriparatide in its domestic market through a tie-up with Teva.

Alvogen And Pfenex Broaden Teriparatide Collaboration

Alvogen and Pfenex have agreed to expand their existing US collaboration on Pfenex’ PF708 teriparatide candidate to also encompass the EU, certain MENA countries and other international markets.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB140323

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel